Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on November 29, 2023, covering events occurring on November 28 and November 29, 2023. The Company is a biopharmaceutical entity focused on developing novel vaccine candidates, including CC-42344 for influenza A.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate events rather than a financial statement.
Material Changes
No material financial changes or operational updates were disclosed in this filing. The report serves to disseminate information regarding a corporate presentation and a subsequent press release.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure: On November 28, 2023, Sam Lee, President and Co-CEO, presented at the World Vaccine Conference.
- Product Candidate: The presentation and a press release issued on November 29, 2023, discussed the Company's CC-42344 influenza A product candidate.
- Availability: A webcast recording of the presentation was made available on the Company's website starting November 29, 2023.
- Legal Status: The information in this Item 7.01 and the accompanying presentation (Exhibit 99.1) is not deemed "filed" under the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review the slide presentation (Exhibit 99.1) and press release (Exhibit 99.2) for specific data on the CC-42344 influenza A candidate.
- Verify the webcast recording on the Company's official website for management commentary not captured in the text.
- Consult the most recent 10-K or 10-Q filings for actual financial metrics, as this 8-K contains no financial data.